SARS-CoV-2 S1 Protein in Monocytes from PASC Patients up to 15 Months Post-Infection

A study of 46 individuals investigates the persistence of SARS-CoV-2 S1 protein in immune cells up to 15 months after acute infection. The dataset, authored by Bruce K. Patterson and shared on figshare, compares T-cell, B-cell, and monocyte subsets in severe COVID-19 patients and those with Post-Acute Sequelae of COVID-19 (PASC). It includes flow cytometry and mass spectrometry confirmation of protein presence in non-classical monocytes.

Use Cases

• Analyzing differences in monocyte subset levels between PASC patients and healthy controls based on CD14 and CD16 markers.
• Investigating the presence of SARS-CoV-2 S1 protein in non-classical monocytes as a potential source of inflammation.
• Comparing immunological markers in severe COVID-19 versus PASC patient cohorts.
• Studying the correlation between fragmented viral RNA and persistent S1 protein in peripheral blood mononuclear cells.

Strengths

• Includes data from 46 individuals, providing a basis for cohort comparison.
• Reports statistically significant findings (e.g., P=0.002 for elevated intermediate monocytes).
• Uses multiple validation methods, including flow cytometric sorting and mass spectrometry.
• Tracks patients up to 15 months post-infection, offering a long-term perspective.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is small (58.1 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Laboratory analysis of patient blood samples using flow cytometry, ddPCR, and mass spectrometry.

Time Range

Up to 15 months post-acute SARS-CoV-2 infection.

Freshness

Last updated 2026-04-23 10:39:16; freshness should be verified.